Oseltamivir for Influenza Postexposure Prophylaxis. Economic Evaluation for Children Aged 1-12 Years in the U.S.

American Journal of Preventive Medicine

Volumn 37, Issue 5, 2009, Pages 381-388

  Talbird, Sandra E ^a   Brogan, Anita J ^a   Winiarski, Aleksander P ^b  

^a RTI INTERNATIONAL   (United States)

^b HOFFMANN LA ROCHE INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OSELTAMIVIR;

ARTICLE; BUDGET; CAREGIVER; CHILD; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DECISION TREE; DRUG EFFICACY; ECONOMIC ASPECT; HEALTH CARE COST; HUMAN; INFECTION PREVENTION; INFLUENZA; MAJOR CLINICAL STUDY; PRESCRIPTION; PRODUCTIVITY; QUALITY ADJUSTED LIFE YEAR; UNITED STATES;

ANTIVIRAL AGENTS; CHILD; CHILD, PRESCHOOL; COST-BENEFIT ANALYSIS; DATABASES, FACTUAL; DECISION TREES; DRUG COSTS; HUMANS; INFANT; INFLUENZA, HUMAN; OSELTAMIVIR; QUALITY-ADJUSTED LIFE YEARS; UNITED STATES;

EID: 70350006676     PISSN: 07493797     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amepre.2009.08.012     Document Type: Article

References (62)

1. CDC. Influenza (2009), CDC, Atlanta GA. www.cdc.gov/flu
2. Neuzil K.M., Mellen B.G., Wright P.F., Mitchel Jr. E.F., and Griffin M.R. The effect of influenza on hospitalizations, outpatient visits, and courses of antibiotics in children. N Engl J Med 342 4 (2000) 225-231
3. Glezen W.P., and Couch R.B. Interpandemic influenza in the Houston area, 1974-76. N Engl J Med 298 11 (1978) 587-592
4. Monto A.S., and Sullivan K.M. Acute respiratory illness in the community. Frequency of illness and the agents involved. Epidemiol Infect 110 1 (1993) 145-160
5. Wright P.F., Ross K.B., Thompson J., and Karzon D.T. Influenza A infections in young children. Primary natural infection and protective efficacy of live-vaccine-induced or naturally acquired immunity. N Engl J Med 296 15 (1977) 829-834
6. Wright P.F., Thompson J., and Karzon D.T. Differing virulence of H1N1 and H3N2 influenza strains. Am J Epidemiol 112 6 (1980) 814-819
7. Fox J.P., Hall C.E., Cooney M.K., and Foy H.M. Influenzavirus infections in Seattle families, 1975-1979. I. Study design, methods and the occurrence of infections by time and age. Am J Epidemiol 116 2 (1982) 212-227
8. Glezen W.P., Keitel W.A., Taber L.H., Piedra P.A., Clover R.D., and Couch R.B. Age distribution of patients with medically-attended illnesses caused by sequential variants of influenza A/H1N1: comparison to age-specific infection rates, 1978-1989. Am J Epidemiol 133 3 (1991) 296-304
9. Longini Jr. I.M., Koopman J.S., Monto A.S., and Fox J.P. Estimating household and community transmission parameters for influenza. Am J Epidemiol 115 5 (1982) 736-751
10. Taber L.H., Paredes A., Glezen W.P., and Couch R.B. Infection with influenza A/Victoria virus in Houston families, 1976. J Hyg (Lond) 86 3 (1981) 303-313
11. Thompson W.W., Shay D.K., Weintraub E., et al. Influenza-associated hospitalizations in the United States. JAMA 292 11 (2004) 1333-1340
12. CDC. Update: influenza activity-United States and worldwide, 2005-06 season, and composition of the 2006-07 influenza vaccine. MMWR Morb Mortal Wkly Rep 55 23 (2006) 648-653
13. Mauskopf J.A., Cates S.C., and Griffin A.D. A pharmacoeconomic model for the treatment of influenza. Pharmacoeconomics 16 S1 (1999) 73-84
14. Szucs T. The socio-economic burden of influenza. J Antimicrob Chemother 44 SB (1999) 11-15
15. Molinari N.A., Ortega-Sanchez I.R., Messonnier M.L., et al. The annual impact of seasonal influenza in the U.S.: measuring disease burden and costs. Vaccine 25 27 (2007) 5086-5096 E-pub 2007 Apr 20
16. Ampofo K., Gesteland P.H., Bender J., et al. Epidemiology, complications, and cost of hospitalization in children with laboratory-confirmed influenza infection. Pediatrics 118 6 (2006) 2409-2417
17. Kavet J. A perspective on the significance of pandemic influenza. Am J Public Health 67 11 (1977) 1063-1070
18. Sullivan K.M. Health impact of influenza in the United States. Pharmacoeconomics 9 S3 (1996) 26-33 50-3
19. Akazawa M., Sindelar J.L., and Paltiel A.D. Economic costs of influenza-related work absenteeism. Value Health 6 2 (2003) 107-115
20. CDC. Influenza vaccination coverage among children aged 6-59 months-six immunization information system sentinel sites, United States, 2006-2007 influenza season. MMWR Morb Mortal Wkly Rep 56 (2007) 963-965
21. Hurwitz E.S., Haber M., Chang A., et al. Effectiveness of influenza vaccination of day-care children in reducing influenza-related morbidity among household contacts. JAMA 284 (2000) 1677-1682
22. Esposito S., Marchisio P., Cavagna R., et al. Effectiveness of influenza vaccination of children with recurrent respiratory tract infections in reducing respiratory-related morbidity within the households. Vaccine 21 (2003) 3162-3168
23. Reichert T.A., Sugaya N., Fedson D.S., Glezen W.P., Simonsen L., and Tashiro M. The Japanese experience with vaccinating schoolchildren against influenza. N Engl J Med 344 (2001) 889-896
24. Piedra P.A., Gaglani M.J., Kozinetz C.A., et al. Herd immunity in adults against influenza-related illnesses with use of the trivalent-live attenuated influenza vaccine (CAIV-T) in children. Vaccine 23 (2005) 1540-1548
25. Monto A.S., Davenport F.M., Napier J.A., and Francis Jr. T. Modification of an outbreak of influenza in Tecumseh, Michigan by vaccination of schoolchildren. J Infect Dis 122 (1970) 16-25
26. American Academy of Pediatrics. Antiviral therapy and prophylaxis for influenza in children. Pediatrics 119 4 (2007) 852-860
27. Hayden F.G., Belshe R., Villanueva C., et al. Management of influenza in households: a prospective, randomized comparison of oseltamivir treatment with or without postexposure prophylaxis. J Infect Dis 189 3 (2004) 440-449
28. Welliver R., Monto A.S., Carewicz O., et al. Effectiveness of oseltamivir in preventing influenza in household contacts: a randomized controlled trial. JAMA 285 6 (2001) 748-754
29. Sander B., Hayden F.G., Gyldmark M., and Garrison Jr. L.P. Post-exposure influenza prophylaxis with oseltamivir: cost effectiveness and cost utility in families in the UK. Pharmacoeconomics 24 4 (2006) 373-386
30. Tappenden P., Jackson R., Cooper K., et al. Amantadine, oseltamivir and zanamivir for the prophylaxis of influenza (including a review of existing guidance no. 67): a systematic review and economic evaluation. Health Technol Assess 13 11 (2009) iii, ix-xii, 1-246
31. Turner D., Wailoo A., Nicholson K., Cooper N., Sutton A., and Abrams K. Systematic review and economic decision modelling for the prevention and treatment of influenza A and B. [review]. Health Technol Assess 7 35 (2003) iii-iv, xi-xiii, 1-170
32. Whitley R.J., Hayden F.G., Reisinger K.S., et al. Oral oseltamivir treatment of influenza in children. Pediatr Infect Dis J 20 2 (2001) 127-133
33. Thompson W.W., Shay D.K., Weintraub E., et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 289 2 (2003) 179-186
34. Nordstrom B.L., Sung I., Suter P., and Szneke P. Risk of pneumonia and other complications of influenza-like illness in patients treated with oseltamivir. Curr Med Res Opin 21 5 (2005) 761-768
35. Healthcare Cost and Utilization Project. Introduction to the HCUP Nationwide Inpatient Sample (NIS), 2004 (2004), Agency for Healthcare Research and Quality, Rockville MD. www.hcup-us.ahrq.gov/db/nation/nis/NIS_Introduction_2004.jsp
36. Fine M.J., Smith M.A., Carson C.A., et al. Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis. JAMA 275 2 (1996) 134-141
37. Mauskopf J.A., Cates S.C., Griffin A.D., Neighbors D.M., Lamb S.C., and Rutherford C. Cost effectiveness of zanamivir for the treatment of influenza in a high risk population in Australia. Pharmacoeconomics 17 6 (2000) 611-620
38. Gilbert D.N., Moellering R.C., Eliopoulos G.M., and Sande M.A. Sanford guide to antimicrobial therapy 2007. 37th ed. (2007), Antimicrobial Therapy Inc, Sperryville VA
39. Smith K.J., and Roberts M.S. Cost-effectiveness of newer treatment strategies for influenza. Am J Med 113 4 (2002) 300-307
40. Prosser L.A., Bridges C.B., Uyeki T.M., et al. Health benefits, risks, and cost-effectiveness of influenza vaccination of children. Emerg Infect Dis 12 (2006) 1548-8
41. Luce B.R., Nichol K.L., Belshe R.B., et al. Cost-effectiveness of live attenuated influenza vaccine versus inactivated influenza vaccine among children aged 24-59 months in the United States. Vaccine 26 23 (2008) 2841-2848 E-pub 2008 May 6
42. Hoyert D.L., Heron M.P., Murphy S.L., and Kung H.C. Deaths: final data for 2003. Natl Vital Stat Rep 54 13 (2006) 1-120
43. Gold M.R., Siegel J.E., Russell L.B., and Weinstein M.C. Cost-effectiveness in health and medicine (1996), Oxford University Press, New York
44. Tamiflu. [package insert] (2006), Roche Laboratories Inc, Nutley NJ
45. McDowell M.A., Fryar C.D., Hirsch R., and Ogden C.L. Anthropometric reference data for children and adults: U.S. population, 1999-2002. Adv Data 361 (2005) 1-5
46. Red Book for Windows. Version 61127. October 2008.
47. Ingenix, Inc. The Essential Resource Based Relative Value Scale: a comprehensive listing of RBRVS values for CPT and HCPCS codes (2008), Ingenix, Inc, Salt Lake City UT
48. U.S. Department of Labor, Bureau of Labor Statistics. National Compensation Survey: occupational earnings table: United States, July 2007. www.bls.gov/ncs/ocs/sp/nctb0300.pdf
49. Prosser L.A., Ray G.T., O'Brien M., Kleinman K., Santoli J., and Lieu T.A. Preferences and willingness to pay for health states prevented by pneumococcal conjugate vaccine. Pediatrics 113 2 (2004) 283-290
50. USDHHS. National Ambulatory Medical Care Survey (NAMCS) (1997), National Center for Health Statistics, Ann Arbor MI
51. Grosse S.D. Productivity loss tables. Appendix I. In: Haddix A.C., Teutsch S.M., and Corso P.S. (Eds). Prevention effectiveness. 2nd ed. (2003), Oxford University Press, New York NY 245-257
52. Alsarraf R., Jung C.J., Perkins J., Crowley C., Alsarraf N.W., and Gates G.A. Measuring the indirect and direct costs of acute otitis media. Arch Otolaryngol Head Neck Surg 125 1 (1999) 12-18
53. Talbird S.E., Brogan A.J., Winiarski A.P., and Sander B. Cost-effectiveness of treating influenzalike illness with oseltamivir in the United States. Am J Health Syst Pharm 66 5 (2009) 469-480
54. U.S. Department of Labor, Bureau of Labor Statistics. Consumer price index, medical care, U.S. city average, not seasonally adjusted. data.bls.gov/PDQ/outside.jsp?survey=cu.
55. Drugstore.com. www.drugstore.com/pharmacy/drugindex/default.asp?trx=1Z5015.
56. Prosser L.A., Bridges C.B., Uyeki T.M., et al. Values for preventing influenza-related morbidity and vaccine adverse events in children. Health Qual Life Outcomes 3 (2005) 18
57. Sander B., Gyldmark M., Hayden F.G., Morris J., Mueller E., and Bergemann R. Influenza treatment with neuraminidase inhibitors: cost-effectiveness and cost-utility in healthy adults in the United Kingdom. Eur J Health Econ 6 3 (2005) 244-252
58. Sander B., Gyldmark M., Aultman R., and Aoki F.Y. Impact on health outcome and costs of influenza treatment with oseltamivir in elderly and high-risk patients. J Med Econ 7 (2004) 67-83
59. Reisinger K., Greene G., Aultman R., Sander B., and Gyldmark M. Effect of influenza treatment with oseltamivir on health outcome and costs in otherwise healthy children. Clin Drug Investig 24 7 (2004) 395-407
60. Postma M.J., Novak A., Scheijbeier H.W., Gyldmark M., van Genugten M.L., and Wilschut J.C. Cost effectiveness of oseltamivir treatment for patients with influenza-like illness who are at increased risk for serious complications of influenza: illustration for the Netherlands. Pharmacoeconomics 25 (2007) 497-509
61. O'Brien B.J., Goeree R., Blackhouse G., Smieja M., and Loeb M. Oseltamivir for treatment of influenza in healthy adults: pooled trial evidence and cost-effectiveness model for Canada. Value Health 6 2 (2003) 116-125
62. Monto A.S., McKimm-Breschkin J.L., Macken C., et al. Detection of influenza viruses resistant to neuraminidase inhibitors in global surveillance during the first 3 years of their use. Antimicrob Agents Chemother 50 7 (2006) 2395-2402